CAMBRIDGE, Mass., March 1, 2012 /PRNewswire/ -- Idenix
Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company
engaged in the discovery and development of drugs for the treatment
of human viral diseases, today announced that it has elected
Thomas R. Hodgson, a current member
and Lead Director of Idenix's Board and former President and Chief
Operating Officer of Abbott Laboratories, to serve as Chairman of
the Board. Additionally, Idenix has appointed Michael S. Wyzga to its Board of Directors and
he will serve as Chairman of the Audit Committee. Mr. Wyzga is
currently President and Chief Executive Officer of Radius Health,
Inc., a leading company developing a new generation of drug
therapies for osteoporosis and women's health. Mr. Wyzga has more
than 20 years of experience in the biotechnology and
high-technology industries providing leadership in the areas of
corporate finance, strategic planning and business development,
most recently serving as Executive Vice President, Finance and
Chief Financial Officer of Genzyme Corporation.
"Tom Hodgson has served on
Idenix's Board for 10 years and he has made significant
contributions to Idenix's progress during that time. I look forward
to his continued guidance and leadership as Chairman," said
Ron Renaud, President and Chief
Executive Officer of Idenix.
Renaud continued, "We are also pleased to have Mike join the
Idenix Board of Directors, bringing a depth of industry experience
from his notable 13-year tenure with Genzyme. His financial
leadership and strategic planning background will be a valuable
asset to the Board as we continue to advance our pipeline of novel
HCV drug candidates."
Prior to joining Radius, Mr. Wyzga was Executive Vice President,
Finance and Chief Financial Officer of Genzyme until its
acquisition by Sanofi in April 2011.
Mr. Wyzga joined Genzyme in 1998 and held primary responsibility
for the firm's financial management worldwide. He provided key
leadership in the successful $20.1
billion sale of Genzyme to Sanofi, which was the
second-largest acquisition in biotechnology history. Prior to
joining Genzyme, Mr. Wyzga was Chief Financial Officer of Sovereign
Hill Software. He previously served as Vice President of Finance
and Chief Financial Officer of CacheLink Corporation, a
client/service software company. Mr. Wyzga also held management
positions at Lotus Development Corporation and Digital Equipment
Corporation. He received an MBA from Providence College and a BS from Suffolk University.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical Company engaged in the discovery and development
of drugs for the treatment of human viral diseases. Idenix's
current focus is on the treatment of patients with hepatitis C
infection. For further information about Idenix, please refer to
www.idenix.com.
Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033
(media)
Teri Dahlman (617) 995-9807
(investors)
SOURCE Idenix Pharmaceuticals, Inc.